Trial reportCanadian journal of veterinary research = Revue canadienne de recherche veterinaire2011
Vaccination with type III secreted proteins leads to decreased shedding in calves after experimental infection with Escherichia coli O157.
Trial report in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review.BMC public health · 2013Pooled it
- Prevalence of selected Shiga toxin-producingJournal of medical microbiology · 2026Article
- Secreted protein NFA47630 from Nocardia farcinica IFM10152 induces immunoprotective effects in mice.Tropical diseases, travel medicine and vaccines · 2024Article
- Article
- A chimeric protein-based vaccine elicits a strong IgG antibody response and confers partial protection against Shiga toxin-producingFrontiers in immunology · 2023Article
- Immunoprotective Analysis of the NFA49590 Protein fromPathogens (Basel, Switzerland) · 2022Article
- Repeated Oral Vaccination of Cattle with Shiga Toxin-Negative Escherichia coli O157:H7 Reduces Carriage of Wild-Type E. coli O157:H7 after Challenge.Applied and environmental microbiology · 2021Article
- The Role ofToxins · 2020Review
- Molecular Biology ofToxins · 2020Review
- On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome.MedChemComm · 2019Review
- OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves.Human vaccines & immunotherapeutics · 2018Article
- Escherichia coli, cattle and the propagation of disease.FEMS microbiology letters · 2017Review
- Citrobacter rodentium mouse model of bacterial infection.Nature protocols · 2016Article
- Article
- Article
- Article
- Strain-dependent cellular immune responses in cattle following Escherichia coli O157:H7 colonization.Infection and immunity · 2014Article
- Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Review
- The enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak.EMBO molecular medicine · 2012Review
- Proteins other than the locus of enterocyte effacement-encoded proteins contribute to Escherichia coli O157:H7 adherence to bovine rectoanal junction stratified squamous epithelial cells.BMC microbiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli O157:H7 remains a threat to humans via cattle-derived fecal contamination of food and water. Preharvest intervention strategies represent a means of reducing the pathogen burden before harvest. In this study, the efficacy of a commercially produced type III secreted protein (TTSP) vaccine was evaluated with the use of a commingled experimental calf infection model (30 placebo-treated animals and 30 vaccinates). The calves were vaccinated on days 0, 21, and 42 and infected with 10(9) colony-forming units (CFU) of E. coli O157 by oral-gastric intubation on day 56. Fecal shedding was monitored daily for 14 d. Serologic assessment revealed a robust immune response to vaccination; the serum titers of antibodies against EspA, Tir, and total TTSPs were significantly higher in the vaccinates than in the placebo-treated animals on days 21, 42, 56, and 70. Significantly less (P = 0.011) of the challenge organism was shed by the vaccinates than by the placebo-treated animals on days 3 to 10. Peak shedding occurred in both groups on days 3 to 6; during this period the vaccinates showed a mean log reduction of 1.4 (P = 0.002) and a mitigated fraction of 51%. The number of animals shedding was significantly lower among the vaccinates compared with the placebo group on days 3 to 6 (P ≤ 0.05), with a mean prevented fraction of 21%. No differences in the duration of shedding were observed. Owing to the low challenge shedding in both groups on days 11 to 14 (mean CFU/g < 10; median = 0), no significant differences were observed. These data indicate that TTSP vaccination had protective effects through significant reductions in the number of animals shedding and the number of challenge organisms shed per animal and provides evidence that TTSP vaccination is an effective preharvest intervention strategy against E. coli O157.
Indexed as
Identifiers
21731179PMC3062931W197872207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.